U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 5 of 5 results

Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)



Anecortave is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. It will be marketed by Alcon as anecortave acetate (AA) for depot suspension under the trade name Retaane. In 2007 the...
mixture
Status:
US Approved Rx (2000)
First approved in 2000

Class:
MIXTURE



Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presume...
Status:
US Approved Rx (2024)
First approved in 2011

Class:
PROTEIN

Status:
US Approved Rx (2021)
First approved in 2006

Class:
PROTEIN

nucleic acid
Status:
US Previously Marketed
First approved in 2004

Class:
NUCLEIC ACID


Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist indicated for the treatment of neovascular (wet) age-related macular degeneration. Pegaptanib is an aptamer, a pegylated modified single-stranded oligonucleotide, which ad...